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ABSTRACT. For 318 patients in 8 different Belgian hospitals, the entire skin–dose
distribution was mapped using a grid of 70 thermoluminescence dosemeters per
patient, allowing an accurate determination of the maximum skin dose (MSD). Dose–
area product (DAP) values, exposure parameters and geometry, together with
procedure, patient and cardiologist characteristics, were also registered. Procedures
were divided into two groups: diagnostic procedures (coronary angiography) and
therapeutic procedures (dilatation, stent, combined procedures (e.g. coronary
angiography + dilatation + stent)). The mean value of the MSD was 0.310 Gy for
diagnostic and 0.699 Gy for therapeutic procedures. The most critical projection for
receiving the MSD is the LAO90 (left anterior oblique) geometry. In 3% of cases, the
MSD exceeded the 2 Gy dose threshold for deterministic effects. Action levels in terms
of DAP values as the basis for a strategy for follow-up of patients for deterministic
radiation skin effects were derived from measured MSD and cumulative DAP values.
Two DAP action levels are proposed. A first DAP action level of 125 Gy cm2
corresponding to the dose threshold of 2 Gy would imply an optional
radiopathological follow-up depending on the cardiologist’s decision. A second DAP
action level of 250 Gy cm2 corresponding to the 3 Gy skin dose would imply a
systematic follow-up. Dose reference levels — 71.3 Gy cm2 for diagnostic and
106.0 Gy cm2 for therapeutic procedures — were derived from the 75 percentile of the
DAP distributions. As a conclusion, we propose that total DAP is registered in patient’s
record file, as it can serve to improve the follow-up of patients for radiation-induced
skin injuries.
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The extensive exposure to X-rays during fluoroscopy-
guided procedures often provides high radiation doses
to the patient’s skin. Several radiation-induced skin
injuries were described in the 1990s [1, 2]. By late 1994,
the Food and Drug Administration (FDA) in the USA
drew attention to this problem and later published
advice on its website [3]. Koenig et al [4] describe more
than 70 skin injuries in their review paper. These injuries
varied from erythema, moist desquamation and ulcera-
tion to necrosis. The reported cases show that the vast
majority of the overexposures took place in the catheter-
isation room during coronary angiography and inter-
ventions [5]. This is not unexpected as the number of
cardiac interventions performed annually exceeds those
of other interventional radiological procedures by an
order of magnitude [5].
Several recommendations for physicians working
extensively with X-rays in interventional cardiology
have been published in an attempt to reduce patient
doses and to avoid radiation-induced injuries [6, 7].
Owing to the complexity of the procedures, radiation-
induced skin injuries still occur, however, even with
contemporary ‘‘state-of-the-art’’ dose-reducing X-ray
systems and appropriate training of physicians.
As stated by the ICRP (International Commission on
Radiological Protection), the risk of skin injuries has to be
estimated for each individual patient in order to provide
adequate follow-up and treatment of these injuries [8].
Dose thresholds of 2 Gy (onset of transient erythema),
3 Gy for maximum skin dose (MSD) or even as low as
1 Gy have been proposed [8]. Therefore, procedures for
estimating and monitoring patient skin dose in daily
practice need to be developed.
Several studies report skin doses received during
interventional cardiology, which were mostly measured
using film or a very limited number of thermolumines-
Address correspondence to: E Bogaert, Medical Physics and
Radiation Protection, Ghent University, Gent, Belgium. E-mail:
Evelien.Bogaert@ugent.be
The British Journal of Radiology, 82 (2009), 303–312
The British Journal of Radiology, April 2009 303
cence dosemeters (TLDs) [9–11]. Owing to the complex-
ity of irradiation geometries, which often involve two X-
ray tubes in a C-arm-type setting at different angles, it is
not easy to predict which location on the patient’s skin is
going to receive the maximum dose. This implies that the
total skin dose distribution has to be mapped so that
MSD received can be measured. Dose distributions were
measured by Suzuki et al [12] using colour-changing
radiosensitive indicators, but for a restricted number of
patients in only one catheterisation room.
Dose–area product (DAP) action levels are defined as
levels of radiation that indicate skin exposures necessi-
tating medical follow-up for possible radiation injuries.
DAP action levels do not provide a guideline for
optimising dose in relation to both medical benefit and
the risk of injury, but dose reference levels (DRLs) do.
Initial national DRL values can be derived from the 75th
percentile of the overall DAP distribution of patients
undergoing a particular procedure. This method of DRL
calculation is indicated when a small number of
catheterisation rooms contribute to the study [13].
Comparing the local mean values with proposed
national DRLs gives an idea of how the current practice
in a hospital ranks with respect to patient dose.
In the present study, action levels derived from
cumulative DAP values are proposed as indicators of skin
dose. These were derived from the measurement of the
entire skin dose distribution using a grid of TLDs, from
which the MSD can be derived. In addition, initial values
for Belgian national DRLs that are derived from diagnostic
and therapeutic DAP distributions are proposed.
Methods
Patients
The patient group comprised 318 adult patients (221
male, 97 female, age range 29–89 years) who underwent
cardiac catheterisation in eight Belgian hospitals during a
period of 2 years (July 2003–July 2005). The hospitals
were selected to be representative of current Belgian
practice. Both university hospitals and private hospitals,
all equipped with contemporary X-ray equipment,
participated in the present study and were chosen to
cover Belgium geographically. Patient demographics are
summarised in Table 1. In each hospital, about 40
patients in one catheterisation room were included in
this study. The cardiac interventional procedures were
divided into two groups: first, diagnostic coronary
angiography, possibly combined with measurement of
pulmonary capillary wedge pressure; second, therapeu-
tic procedures, namely single or multiple percutaneous
transluminal coronary angioplasty (PTCA) with or
without single or multiple consecutive stenting, single
or plural direct stenting and combined (diagnostic plus
therapeutic) procedures. The procedures were per-
formed by experienced cardiologists or medical doctors
undergoing interventional cardiology training, all using
their own protocols. A total of 200 diagnostic and 118
therapeutic procedures were included in this study.
X-ray equipment and DAP meters
The measurements were performed on different
contemporary cardiac X-ray systems (Table 2). All tubes
had an inherent filtration of 2.5 mm Al. X-ray equipment
that was provided with ‘‘fixed filtration’’ insertion was
distinguished from that with ‘‘variable filtration’’ inser-
tion. A system with variable filtration adapts filtration
thickness and material (Al or Cu) according to the
thickness of the tissue being X-rayed, without the
cardiologist’s involvement. If the X-ray equipment has
fixed filtration, the cardiologist must choose a filtration
setting from a limited number of possible filtration
settings. All possible filtration settings used in each
hospital in either fluoroscopy or cinegraphy mode are
given in Table 2. Generally, a combination of an
aluminium filtration of a particular thickness and one
or more copper filters of different thicknesses is used.
All X-ray tubes operated in a pulsed mode, and
controlled tube voltage and anode current with auto-
matic brightness control. All tubes were equipped with
an integrated DAP meter (PTW). The DAP meters were
calibrated in situ for different tube voltages, filtrations
and modes (fluoroscopy or cinegraphy) with a 60 cc
ionisation chamber (Radcal, 10X5-60, Dutoit Medical)
and 33 6 41 cm Kodak X-Omat V films (Eastman
Kodak) for determination of field size.
Table 1. Patient demographics and radiation dose parameters for diagnostic and therapeutic procedures
Diagnostic procedures Therapeutic procedures
Mean (range) Median Mean (range) Median
Patient demographics
Number of males 130 91
Number of females 70 27
Weight of males (kg) 81 82
Weight of females (kg) 71 71
Age (years) 67 (29–86) 65 (31–89)
BMI (kg m–2) 27 (19–49) 28 (20–47)
Measured and calculated radiation dose parameters
MSD (Gy) 0.31 (0.03–2.62) 0.20 0.70 (0.06–4.50) 0.46
DAP (Gy cm2) 55.7 (2.71–265) 43.8 81.5 (10.3–404) 65.4
% contribution of fluoro to DAP 33 (8–90) 50 (9–91)
% contribution of cine to DAP 67 (8–90) 50 (9–91)
BMI, body mass index; DAP, dose–area product; MSD, maximum skin dose.
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Acquisition of exposure and procedure parameters
Each irradiation geometry was determined by a set of
two angles per tube, using the radiological convention
for geometry setting: cranial and caudal rotations in the
sagittal plane and left anterior oblique (LAO) and right
anterior oblique (RAO) rotations in the transverse plane.
For each projection used in the cardiovascular inter-
vention, geometry, tube potential, filtration settings per
mode, number of frames, source to image detector
distance, image detector field size, number of frames
per second, tube current, pulse duration, and mode
(fluoroscopy or cinegraphy) were registered. Cumulative
DAP and DAP rate as a function of time during the
procedure were registered online (Figure 1) by connect-
ing the PTW DAP meter to a Diamentor M4 readout unit
and a laptop. This allowed us to measure DAP
contribution for each mode and projection.
After each intervention, the following information was
recorded: complexity of the intervention (subjective score 1
to 3: ‘‘easy’’, ‘‘normal’’ and ‘‘difficult’’), amount of contrast
used, cardiologist’s experience (specialist or trainee),
standard protocol used for the intervention, and patient’s
data (gender, age, weight, height and chest circumference).
The three-point scale for the complexity score was based
on the duration of the procedures with respect to an
equivalent procedure under normal circumstances, the
number of lesions, the accessibility of the coronary arteries
and the number of frames in one fixed position.
Skin dose measurements
A two-dimensional array of 70 TLDs (MTS-N type,
Poland) covering the patient’s chest was used to measure
the skin–dose distributions of 318 patients in eight
cardiological centres. A ‘‘wrap-around’’ was used to
attach the TLDs to the patient’s skin, which provided a
grid of 30 6 97.5 cm divided into squares of 7.5 6
7.5 cm. TLDs were wrapped in protective plastic and
labelled with their position to enable reconstruction of
the skin–dose distribution. The patient’s chest was
covered completely with the wrap-around, with the
middle centred at the spine and the upper end at a height
corresponding to the sternum. All patients were asked to
keep their arms upwards with their hands behind the
neck during the procedure. The wrap-around with the
TLDs did not affect image quality as they were made of
material (cotton for the wrap-around and LiF:Mg,Ti for
the TLDs) that was not radio-opaque. Neither the wrap-
around nor the individual TLDs were visible on the
radiographic cardiovascular images.
All TLDs were calibrated at the Standard Dosimetry
Laboratory in Ghent (Belgium) at the beginning and at the
end of the study at the beam quality that was used in situ.
Read-out was performed with a Harshaw 3500 reader
(Thermo Electron Corp.). For the study, TLDs were
selected with calibration factors within a 5% range. The
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Bi, biplane; II, image intensifier; FD, flat detector; Mono, monoplane.
Figure 1. Typical output of the DAP registration program:
cumulated DAP (dark line) and DAP rate (light line) as
functions of time. This example shows nine cinegraphy runs
with fluoroscopy in between.
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maximum difference between the calibration factors at the
beginning and the end of the study was less than 10%,
which is the overall uncertainty in the measured MSD.
A graphical representation of the three-dimensional
skin dose distribution was achieved by plotting TLD
data on a mathematical cylindrical phantom represent-
ing the patient, taking into account the circumference of
the wrap-around around the patient’s chest (Figure 2).
DAP was calculated from the measured TLD skin dose
and compared with measured DAP multiplied by a
factor that takes into account the backscatter of the
patient [14]. A very good correlation (r50.95) with a
conversion factor of 1.03 was obtained, confirming the
reliability of the DAP and TLD measurement sets.
Statistical analysis
As multiple factors can influence radiation dose
measurements and calculations, we used a multifactor
analysis of variance (ANOVA). Factors in the ANOVA
design included the differences between hospitals, the
difficulty of the procedure, system of beam filtration
insertion and type of equipment (bi/monoplane, digital
flat panel or conventional image intensifier). Levene’s
test was used to test the homogeneity of the variances
between groups. A non-significant result of the Levene’s
test assured a correct application of the ANOVA
analysis. Pillai’s trace was used as a robust indicator of
significance in the ANOVA analysis [15].
In cases where only two groups were compared, a
non-parametric two-tailed Mann–Whitney test was
performed. Correlations between groups were calculated
by means of the non-parametric Spearman’s rank
correlation coefficient (r). To calculate the regression
coefficients of the relation between two quantities, linear
regression analysis was performed using the Levenberg–
Marquardt algorithm. The relation between cumulative
DAP and MSD was examined by the weighted least
squares method, using heteroscedasticity for determina-
tion of weighting factors. Fitting and p-values were
calculated using ‘‘the R-project’’ [16].
In all statistical calculations, a confidence interval of
95% was applied. Hence, a p-value,0.05 was considered
as significant. All calculations were performed using the
SPSS 12.0 software (SPSS, Chicago).
Results
Maximum skin dose
Radiation dose measurements are summarized in
Table 1. The mean value of MSD was 0.31 Gy and
Figure 2. Three-dimensional representation of skin–dose distribution (mGy) for a coronary angiography in a biplane setting.
TLD positions are indicated. Left: view from the back of the patient. Right: view from the right side of the patient.
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0.70 Gy for diagnostic and therapeutic procedures,
respectively. The difference between these mean values
was significant at a level of p50.001. The median MSDs
were 0.20 Gy and 0.46 Gy for diagnostic and therapeutic
procedures, respectively. Figure 3 shows MSD values
(expressed as a histogram in intervals of 0.25 Gy) for
both diagnostic and therapeutic procedures with their
mean values represented by vertical lines. A multifactor
ANOVA was performed to check whether factors other
than the type of procedure (diagnostic or therapeutic)
affect the MSD. Both flat panel equipment and the use of
biplane configurations did not significantly lower MSD
(p50.828 and p50.626, respectively). The lowest MSD
values were recorded with systems equipped with
variable filtration settings (p50.033). The MSD also
depends significantly on the difficulty of the procedures
(p,0.001). In the three-point difficulty scale used in this
study, levels 2 and 3 resulted in significantly greater
MSD values than did the easiest (level 1) procedures.
ANOVA identified no significant differences in MSDs
recorded in different hospitals (p50.171), partly because
of large variations within in the MSD data set.
Nonetheless, some clear trends were observed: in some
hospitals higher mean MSDs could be explained by the
continuous use of the fluoroscopy ‘‘high’’ mode for
fluoroscopy filtration setting. This mode uses least beam
filtration during exposure. In other hospitals, high doses
could be explained by the training of doctors in
percutaneous transluminal coronary angioplasty (PTCA)
and stenting during the study period. Low mean MSDs
are often related to ‘‘good practice’’ in terms of the
amount of radiation used on a monoplane system.
Alternatively, they may be explained by a local clinical
practice in which coronary angiography is performed a
few days before the therapeutic intervention, and is not
therefore taken into account in the skin–dose distribution.
The angle of the projections under which the MSD was
received by the patient could be deduced from the TLD
measurements. These angles, measured in a transverse
plane through the patient, are plotted as a histogram in
Figure 4. The sagittal angulations of the X-ray beam were
not taken into account in this figure. The lateral
projection (LAO90) is the most frequent projection
leading to the MSD, in agreement with Kuon et al. [17].
This projection involves a closer positioning of the tube
to the patient’s skin, and an increase in exposure is
related to the fact that patients’ chests are thicker in the
lateral than in the anteroposterior dimension. The
probability that the skin will be exposed to the MSD
decreases steadily from lateral right to the centre of the
back with a second prominent peak at the back left to the
spine from the RAO30 projection. The angular distribu-
tion of the MSD indicates the necessity of using a large
TLD set covering the whole chest for MSD determination
in interventional cardiology.
For therapeutic procedures, the highest measured
MSD was 4.50 Gy, whereas for diagnostic procedures
this value was 2.62 Gy. 1% of the diagnostic procedures
(n52) and 6% of the therapeutic procedures (n57)
exceeded the threshold of 2 Gy for deterministic skin
effects. An overview of these cases is given in Table 3.
The therapeutic procedures were all ‘‘combined proce-
dures’’ in which a diagnostic examination preceded a
therapeutic intervention, except for case 2, which
involved a merely therapeutic intervention. In three out
of the nine cases in which the 2 Gy threshold was
exceeded, a trainee was involved.
We also looked at the percentage contributions of
fluoroscopy and cinegraphy to the DAP registered for the
geometries that caused MSDs exceeding 2 Gy. In five of
the nine cases, a long fluoroscopy projection was
obviously responsible for the high skin dose (contribution
.75%). Investigation of these exposures in detail shows
that the main reason for high skin dosage is complexity of
the examinations, with the most complex interventions
necessitating a greater X-ray exposure for the guidance of
the catheter and imaging (p,0.001). All patients with
MSDs of 2 Gy and higher belonged to the high-difficulty
group. According to our study, important factors that lead
to high skin doses are high patient weight, prolonged use
of one and the same projection (in both cinegraphy and
fluoroscopy) and a relatively large distance between
patient and image receptor, which reduces the distance
between X-ray source and patient in a C-arm setting.
Dose–area product
The mean value of DAP for diagnostic procedures was
55.7 Gy cm2, which differed significantly (p,0.001) from
that for therapeutic procedures (81.5 Gy cm2). The
corresponding 75th percentile values were 71.3 Gy cm2
and 106.6 Gy cm2 for diagnostic and therapeutic proce-
dures, respectively. Table 4 gives an overview of mean
DAP values for the different hospitals in the study, for
comparison with the proposed DRLs. DAP values differ
significantly among the hospitals (p,0.001). Significant
differences were also found between monoplane and
biplane systems, with lower DAP values for monoplane
systems (p50.026) (mean 59.6 Gy cm2 for monoplane
versus 74.6 Gy cm2 for biplane systems). When a
variable filtration setting was available, lower DAPs
were recorded (mean DAP values of 49.2 Gy cm2 for
variable versus 91.4 Gy cm2 for fixed filtration settings
p,0.001). The installation of a digital flat panel detector
generally resulted in DAPs that were lower than those
recorded in image intensifier systems (mean DAP values
Figure 3. Histogram of maximum skin dose (Gy) for
diagnostic (solid line) and therapeutic (dashed line) proce-
dures. Mean values are indicated by vertical lines.
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of 57.4 Gy cm2 versus 70.0 Gy cm2, respectively), but
this finding did not reach statistical significance
(p50.068). Apart from the factors just mentioned, the
higher DAPs recorded in some hospitals are also due to
cardiologists in training performing procedures during
the study, and the continuous use of the fluoroscopy
high-contrast mode (minimum filtration).
The mean contribution of fluoroscopy to DAP in
diagnostic procedures was 33%, whereas this contribution
was 50% in therapeutic procedures (p50.002). In general,
contributions of fluoroscopy and cine to the total DAP
values varied significantly depending on the hospital
(p50.017). The level of procedure difficulty also had a
significant influence (p,0.001) with an enhancement of
the fluoroscopy contribution in difficult procedures. For
diagnostic procedures, hospitals with biplane systems
have a significantly larger contribution of cinegraphy than
hospitals with a monoplane system (p50.001). This means
that the possibility of acquiring two cinegraphy runs
simultaneously at two different projections in a biplane
system is not fully exploited but rather leads to an overuse
due to the ease and speed of the technique. For
therapeutic procedures, these trends are not so prominent.
Figure 5 shows DAP values for diagnostic and
therapeutic procedures. The distributions are strongly
skewed and the 75th percentile values are indicated by
vertical lines. Taking into account the number of
catheterisation rooms that were considered, these values
are proposed as initial national Belgian DRLs.
Maximum skin dose vs dose area product
The relation between cumulative DAP and MSD was
investigated for both diagnostic and therapeutic inter-
ventions based on all hospital data. These data are
presented graphically in Figure 6. Different symbols are
used to highlight the impact of the difficulty of the
procedures. The regression line for bulk data and a trend
line for outlying points are indicated. For bulk data, a
linear relationship was considered as a first approxima-
tion and yielded a p,0.001. The mathematical function
(c.DAPd) chosen for the outlying points was based on
their DAP dependence and to fulfil criteria of physical
relevance (passing through origin and continuously
increasing function). p-values for parameters c (0.113)
and d (0.591) were 0.064 (p slightly .0.05) and lower
than 0.001. The fit served as a guiding tool for the
derivation of DAP action levels. DAP values of
125 Gy cm2 and 250 Gy cm2, corresponding to 2 and
3 Gy MSD levels, can be deduced from these data.
Discussion
Maximum skin dose and dose-area product
The mean MSDs recorded in this large-scale study,
0.31 Gy for diagnostic and 0.70 Gy for therapeutic
procedures, confirm the high values for MSD in smaller
Table 3. Summary of the cases in which the maximum skin dose exceeded 2 Gy
Case
No.
Procedure MSD (Gy) Angle MSD (˚) Patient’s
gender
Cardiologist DAP (Gy cm2) Contribution of
fluoro to MSD (%)
Contribution of cine
to MSD (%)
1 D 2.1 100 F Tr+Doc 194 57 43
2 T 2.5 244 M Tr 298 30 70
3 T 2.4 66 M Doc 154 77 23
4 T 3.1 247 M Doc 153 40 30
5 T 2.3 215 M Doc 131 27 73
6 T 3.2 14 F Tr+Doc 404 95 5
7 T 3.4 45 M Doc 315 98 2
8 T 4.5 95 M Doc 257 89 11
9 D 2.6 94 F Doc 191 79 21
D, diagnostic; T, therapeutic; Tr, trainee; Doc, doctor-cardiologist.
Figure 4. Distribution of the angles
under which maximum skin dose
(MSD) was received by the patient.
The co-ordinate system is centred at
the centre of the mathematical
cylindrical patient. 0 degrees means
anteroposterior (AP) projection
and 90 degrees means lateral (LAT)
projection.
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studies published previously: 0.270 Gy [18, 19] for
diagnostic procedures and 0.760 Gy [20] and 0.980 Gy
[19] for therapeutic procedures. Mean MSDs as low as
0.113 Gy [21] and 0.217 Gy [22] for diagnostic proce-
dures and 0.391 Gy [22] for therapeutic procedures have
also been reported, but these were measured using only
a limited number of TLDs, which may explain the
differences from the present work. In nine patients, (3%
of all patients investigated), the dose threshold for
deterministic effects to the skin, 2 Gy, was exceeded.
This percentage can be considered to be representative
for contemporary clinical practice in Belgium.
Mean and median values for cumulative DAP dis-
tributions over all patients undergoing diagnostic and
therapeutic procedures in this study are within the data
ranges reported in the literature. A comparison with
literature data can be found in Table 5 [18, 21, 23, 24].
DAP action levels
Interpretation of Figure 6 shows that cumulative DAP
can serve as a real-time indicator of action levels for
MSD. The trend line through the outlying data points
results in DAP action levels of 125 Gy cm2 and
250 Gy cm2 for 2 Gy and 3 Gy MSD levels, respectively.
This trend line is based on the behaviour of outlying
MSD values, representing the highest skin doses
obtained in this study. It serves as a guiding tool for
the derivation of DAP action levels. The function is not
applicable for low DAP values nor for values outside the
range of the measured data. It does not represent a
general relationship between MSD and DAP as it was
based only on outlying points. According to the data in
the present study, the cumulative probability of an MSD
exceeding the 2 Gy threshold is 30% when the DAP
exceeds the action level of 125 Gy cm2. Analogously, the
cumulative probability of MSD exceeding the 3 Gy level
is 60% when the DAP exceeds 250 Gy cm2. As these DAP
readings can be considered as DAP action levels for both
diagnostic and therapeutic procedures, systematic regis-
tration of the DAP value at the end of the procedure in
the patient’s record is indicated.
When the DAP exceeds 125 Gy cm2, registration in the
patient’s record of the entry site of the beam responsible
for the highest skin dose (together with the DAP value) is
indicated. The cardiologist may also decide whether the
patient needs to be followed up for radiation skin effects
on the basis of the difficulty of the procedure and the
total fluoroscopy time, especially in single projection
directions. This decision has to be based on a comparison
with the local reference procedure.
At the 3 Gy action level (250 Gy cm2), the patient and
his/her personal physician should be informed of the
possible radiation effects. In view of the higher prob-
ability of skin overexposures in therapeutic interven-
tions, this action level is indicated for therapeutic
interventions. In our multicentre study, four interven-
tions (all therapeutic) resulted in skin doses exceeding
3 Gy (1% of all procedures or 3% of the therapeutic
interventions). In our study, one patient with a DAP
value of 153 Gy cm2 and a skin dose of 3.1 Gy can be
considered as a false negative. The DAP action level
determined by our study, 250 Gy cm2, is somewhat
lower than the level resulting from the European
DIMOND III project (300 Gy cm2) [25].
According to ICRP publication 85 [8], an additional
level of 1 Gy should be considered for procedures that
are likely to be repeated. This is applicable to patients
undergoing PTCA because a significant number of them
need a repeat PTCA or additional coronary procedures.
We conclude that a 1 Gy action level is not relevant as
this is only half of the threshold dose and the skin site
exposed to the MSD can only be estimated by the
cardiologist. A 1 Gy action level would be applicable to a
large fraction of the treated patients: in our study 25% of
those undergoing therapeutic procedures. Also, a differ-
ence in action level between diagnostic and therapeutic
procedures, as recommended by the ICRP, is not relevant
Table 4. Mean values for dose–area product values (Gy cm2)









Dose reference level derived from this study 71.3 106.0
Figure 5. Histogram of dose–area product (DAP) (Gy cm2)
for diagnostic (solid line) and therapeutic (dashed line)
procedures. The third quartiles are marked by vertical lines
and represent the proposed Belgian dose reference levels
(DRLs) .
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as in some hospitals a diagnostic procedure precedes a
therapeutic intervention by a few days.
Dose reference levels
At the end of the EC DIMOND II project in 1999, the
following DRLs were proposed: 67 Gy cm2 for coronary
angiography and 110 Gy cm2 for PTCA [26]. The 75th
percentile data obtained in present study, 71.3 Gy cm2
and 106.0 Gy cm2 for diagnostic and therapeutic proce-
dures, respectively, support these DRLs. When applying
these reference levels to the mean DAP values from the
Belgian hospitals, five of the cardiological centres pass
for diagnostic interventions and six for therapeutic
interventions. However, a subsequent EC project
(DIMOND III, 2003) proposed new DRLs based on the
75th percentiles: 45 Gy cm2 for coronary angiography
and 75 Gy cm2 for PTCA [25]. When applying these
more stringent DRLs, only three of the Belgian cardio-
logical centres in our study would pass for diagnostic
interventions and four for therapeutic interventions.
In Figure 7, the mean and the 75th percentile values
for DAP of diagnostic and therapeutic cardiac interven-
tions obtained in the present Belgian study are compared
with the data reported by Neofotistou et al. [25] for
different European countries as a result of the European
DIMOND III project. It is apparent that DAP values in
Belgium are relatively high in comparison with those
obtained in other European countries, both for coronary
angiography and for therapeutic interventions.
Training programmes and quality control
The lower reference values of DIMOND III compared
with the previously proposed ones were explained by the
continued education and training of personnel involved
in interventional cardiology procedures and the increase
of constancy checks on the X-ray systems. The skin dose
distribution data obtained in the present study support
practical training programmes dedicated to patient skin
dose reduction in interventional cardiology. Besides the
emphasis on dose reduction techniques, these pro-
grammes should also focus on the relevance of DAP
values as guidelines for the optimisation of procedure
protocols in terms of radiation protection and prediction
of radiation-induced skin injuries. Furthermore, annual
quality-control checks on the X-ray equipment should be
performed. The systematic registration of DAP for
interventional procedures imposed by present Belgian
legislationwill allow a comparison of hospital DAP values
with the DRLs proposed in this paper, and will lead
towards the optimisation of radiation exposure. The
impact of training programmes and quality control on
patient dose will emerge from follow-up on the database
of patient DAP values. This will allow updating of the
DRLs, very probably to values lower than those presented
here and closer to those proposed by DIMOND III.
It must be kept in mind that DAP action levels and
DRLs are neither dose constraints nor dose limits. They
are investigation tools for the identification of unusually
high levels of radiation that call for investigation if
substantially exceeded [27].
Figure 6. Maximum skin dose
(MSD) (Gy) versus dose–area product
(DAP) (Gy cm2) for all procedures.
DAP levels of 125 Gy cm2 and
250 Gy cm2 (vertical lines) corre-
spond to action levels for skin doses
of 2 Gy and 3 Gy, respectively. The
different symbols refer to the com-
plexity of the procedure. Outlying
points are represented in squared
symbols.
Table 5. Mean and median dose–area product (DAP) values for diagnostic and therapeutic procedures in interventional
cardiology and from data in the literature








Zorzetto et al. [18] 39 CA 55.9 52.5 19 PTCA 91.8 82.6
Van˜o et al. [21] 288 CA 66.5 45.7 45 PTCA 87.5 66.7
Padovani et al. [23] 76 CA-LV 55.9 54 PTCA 101.9
Karambatsakidou et al. [24] 20 CA 49.0 40 PTCA 40.0
Present work 200 CA 55.7 43.7 118 therap 81.5 65.4
CA, coronary angiography; CA-LV, left catheterism + coronary angiography + left ventriculography + 1–2 other acquisitions;
PTCA, percutaneous transluminal coronary angioplasty; therap, therapeutic procedures as defined in present work.
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Conclusions
Cumulative DAP can serve as an online monitor to
provide the interventionist with an immediately readable
dose display representing the MSD. Therefore, systema-
tic registration of this DAP in a patient’s record at the
end of the procedure is necessary. If DAP exceeds
125 Gy cm2 (corresponding to an MSD of 2 Gy), regis-
tration in the patient’s record of the entry site of the beam
responsible for the highest skin dose is indicated.
Possible follow-up of the patient for radiation skin
effects is at the cardiologist’s discretion. If DAP exceeds
250 Gy cm2 (corresponding to an MSD of 3 Gy), the
patient and his/her personal physician should be
informed of the possible radiation effects. A systematic
follow-up should be performed.
In the present study, 71.3 Gy cm2 and 106.0 Gy cm2
are proposed as national DRLs for diagnostic and
therapeutic procedures, respectively, in Belgium. Local
mean values should be compared with these values in
view of optimisation of patient dose.
The present study supports practical training pro-
grammes in interventional cardiology. Besides empha-
sising dose-reduction techniques, these programmes
should also focus on the relevance of DAP as a guide
for optimisation of procedure protocols with respect to
radiation protection and the prediction of radiation-
induced skin injuries.
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